Vaxcyte Shares Surge on Pneumococcal Vaccine Trial Success
Vaxcyte announced its experimental pneumococcal vaccine achieved its primary endpoints in a late-stage trial for adults aged 50 and older, causing its shares to jump 91% pre-market.
Story updates
10:46:49 AM UTC
SquawkNews
By Kelly CloonanVaxcyte said its pneumococcal conjugate vaccine candidate met all primary endpoints in a recent Phase 3 trial.The vaccine company said Monday it will use the study results to file an application with the Food and Drug Administration in the first half of 2028 to get permission to mar…
Vaxcyte said on Monday that its experimental pneumococcal vaccine met its main goals in a late-stage study in adults aged 50 and older, with the stock up 91% before the bell.